Enhanced survival of mice infused with bone marrow‐derived as compared with adipose‐derived mesenchymal stem cells

  • Shogo Shiratsuki
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Shuji Terai
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Yasuhiko Murata
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Taro Takami
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Naoki Yamamoto
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Koichi Fujisawa
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Guzel Burganova
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Luiz Fernando Quintanilha
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan
  • Isao Sakaida
    Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Japan

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Less invasive therapies using mesenchymal stem cells (MSC) are being developed to treat patients with severe liver cirrhosis. MSC constitute a promising cell source for regenerative therapy and are frequently isolated from bone marrow (BMSC) or adipose tissue (ASC). Therefore, this study assessed the characteristics of these two cell types and their safety for cell infusion.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p><jats:italic>In vitro</jats:italic>, exhaustive genetic analysis was performed using human (h)BMSC and hASC. Subsequently, the expression of mRNA and protein was evaluated. <jats:italic>In vivo</jats:italic>, mouse (m)BMSC or mASC was infused into serial mice via the peripheral vein, and 24‐h survival rate, prothrombin time and cause of death were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>On polymerase chain reaction, western blotting, enzyme‐linked immunoassay and fluorescence‐activated cell sorting, tissue factor was found to be expressed at higher levels in hASC than in hBMSC. Prothrombin time in mice infused with mASC (>120 s) was markedly longer than that of untreated mice (6.5 ± 1.7 s) and that of mice infused with BMSC (6.7 ± 0.8 s) (<jats:italic>P</jats:italic> < 0.001), indicating that pro‐coagulation activity was potently enhanced after ASC infusion. The 24‐h survival rates in the mASC‐ and mBMSC‐infused groups were 46.4% (13/28) and 95.5% (21/22), respectively; in the former, the rate decreased with increasing number of infused mASC. This cell number‐dependent effect was not observed with mBMSC. A histopathological analysis of mice that died immediately following mASC infusion revealed multiple thrombi in the blood vessels of the lungs.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results indicate that BMSC are a superior and safer cell source for regenerative therapy.</jats:p></jats:sec>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (9)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ